How many drugs treat Invasive Bladder Malignancy?

Drug Landscape tracks 7 marketed treatments for Invasive Bladder Malignancy (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/invasive-bladder-malignancy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Invasive Bladder Malignancy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Invasive Bladder Malignancy (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Invasive Bladder Malignancy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Platinol-Aq	cisplatin	Pfizer	Platinum-based Drug [EPC]	D(3) dopamine receptor	1978-01-01
Liposomal Doxorubicin	liposomal-doxorubicin	Pfizer	doxorubicin	72 kDa type IV collagenase	1974-01-01
Doxorubicin Hydrochloride	doxorubicin	Pfizer	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Adriamycin	Adriamycin	Johann Wolfgang Goethe University Hospital		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Hydroxydaunomycin	Hydroxydaunomycin	Weill Medical College of Cornell University		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Hydroxydaunorubicin	Hydroxydaunorubicin	University of Colorado, Denver		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
adriacin	adriacin	Chipscreen Biosciences, Ltd.		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Invasive Bladder Malignancy
Chipscreen Biosciences, Ltd. · 1 drug in Invasive Bladder Malignancy
Johann Wolfgang Goethe University Hospital · 1 drug in Invasive Bladder Malignancy
University of Colorado, Denver · 1 drug in Invasive Bladder Malignancy
Weill Medical College of Cornell University · 1 drug in Invasive Bladder Malignancy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Invasive Bladder Malignancy:

Cite this brief

Drug Landscape (2026). Invasive Bladder Malignancy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/invasive-bladder-malignancy. Accessed 2026-06-10.

Invasive Bladder Malignancy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing